Exhibit 99.2

Evogene at a Glance…July, 2019 Ofer Haviv, President & CEO

Safe Harbor Statement * This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “roadmap”, “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *

What We Do… * We revolutionize the product development process in life-science based markets… …through the use of a unique Computational Predictive Biology (CPB) platform

What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *

The Challenge - Product Development Common Practice * Successful Product Launch Extremely low probability of successLong time to market High development costs Limited ‘next generation’ products in pipelines Candidates mainly addressing the first criterion Product Definition Efficacy Stability Shelf-life Safety

The Desired SolutionCandidates with the highest probability of success * Candidates addressing the majority of product criteria at Stage Zero Increasing probability of successReducing time to marketReducing budget Successful Product Launch

Evogene’s Unique Product Development Approach * Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at ‘Stage Zero’ Successful Product Launch The CPB platform targeting to make it possible Increasing probability of successReducing time to marketReducing budget

Microbes Prediction of Candidates for Life-Science Based Products * Genetic Elements Small Molecules \\ \\ Prism Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Bacterial genes – toxins for insects Essential genes – target for herbicides Small chemical molecules – associated to targeted proteins Optimized small chemical molecule – improved commercial viability Plant microbes – associated to specific plant traits Human microbes – associated with human diseases * (under-development) CPB platform

What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *

Targeted Markets * Red - Human HealthMedical CannabisPharmaceutical industryMedical applicationDiagnostics Green - AgricultureAg-ChemicalsSeedsAg-BiologicalsPrecision AgLivestockBiomaterialsEnergy Blue - AquamarineAquacultureHealth White- IndustrialIndustrial applicationPolymersEnzymesBacteria Red White Blue Green Castor oil Ag-Biologicals Ag-Chemicals Seed Traits Human Microbiome Therapeutics Biotechnology for life science industries Medical Cannabis CPB platform

What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *

Corporate Structure & Activities * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor OilCastor Seeds &Growth protocol Agriculture Human Health Industrial Applications CPB platform 100% 100% 100% 90% 100% 100%

Main Collaborations * Ag Biologicals Seed Traits (division) Medical Cannabis Human Microbiome Ag Chemicals Castor Oil Agriculture Human Health Industrial Applications CPB platform 100% 100% 100% 90% 100% 100% CASA

Milestone Roadmap * 2019 Complete two cannabis growth cycles Complete semi-commercial field trials 2020 Enter pre-clinical trials in 2 additional programs; positive results in at least one study Complete first pre-clinical study in oncology Advance product pipeline in wheat bio-stimulants Enter new collaboration agreement Enter commercial scale field trials Demonstrate first desired cannabis trait Reach ‘Lead’ in herbicide program Complete semi-commercial trials toward 2022 commercialization Achieve non-regulated approval for genome-edited soybean products for nematodes Ag seeds Achieve genome-edited soybean lines for nematode resistance Ag seeds Achieve commercial efficacy level, in-vitro, for at least one toxin Ag seeds Positive results in soybean/corn for insect control trait Ag seeds

What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *

Evogene at a Glance… Summary Main collaborations with world-leading companies : Our technology – the CPB platform:Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at ‘Stage Zero’. CPB capabilities for prediction of innovation : Genetic elements – controlling desired biological processesSmall molecules – active ingredients for chemical based products Microbes – active ingredients for microbial based products Target markets and current activities: Agriculture - Ag-Chemicals, Seed Traits, Ag-BiologicalsHuman Health – Human Microbiome, Drug Discovery, Medical CannabisIndustrial Applications – Castor oil Corporate structure: Evogene and the CPB platform at the heart of a group of subsidiaries, each focused in different life-science based markets, with exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline. What we do:We revolutionize the product development process in life-science based markets through the use of a unique Computational Predictive Biology (CPB) platform. Financial fundamentals -Cash position - $ 46 M (June 30, 2019), no debtListed on TASE (2007) and NASDAQ (2013)

Evogene at a Glance…July, 2019 Ofer Haviv, President & CEO Thank You! Contact:investors@evogene.comT: +972 8 931 1963

* Annex I: Subsidiary Overview

Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor OilCastor Seeds &Growth protocol Agriculture Human Health Industrial Applications CPB platform 100% 100% 100% 90% 100% 100%

AgPlenus (Ag-Chemicals) - Mission & Products * Herbicides –Market size: $25B* (2018), growing market need for novel herbicides with improved safety profile and solution for increasing resistance to current herbicides Insecticides - Market size: $15B* (2018), growing market need for improved insecticide selectivity and solution for increasing resistance to current insecticides Mission: design effective and sustainable crop protection products by leveraging predictive biology Main Products under development: *Source: Phillips McDougall

Business Model – Delivering De-Risked Lead Candidates * Discovery Lead Optimization Continued development & regulation Target Hit Lead Optimized Lead Commercial-level efficacySolid business case Commercial-level efficacySolid business caseSelective pre-regulatory data Indication for commercial-level efficacyNovelty driving business case Starting point for commercial-level efficacy & novelty De-risking AgPlenus strategic focus Delivering de-risked Lead candidates targeting large multinational agrochemical companies

AgPlenus (Ag-Chemicals) - Pipeline * Discovery Lead Optimization Herbicides Novel model of action(non-selective/selective) Insecticides Novel site of actionbroad spectrum Fungicides Existing mode of actionoptimization Optimized lead Lead Hit Target 5 targets/sites Final product Continued development 10 scaffolds 3 scaffolds Herbicides Existing mode of actionoptimization 1 scaffold Novel MoA/SoA AI optimization Novel herbicides - new mode of action (2016) Novel insecticides - new site of action (2018) Novel crop enhancers development (2017) Ongoing collaborations – vote of confidence from leading Ag players

Lavie Bio (Ag-Biologicals) - Mission & Products * Mission: Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products Bio-Stimulant – Market size: $2B* (2016), Microbial based targeting yield improvement in row crops such as corn, wheatBio-Pesticides (Bio-Insecticides & Bio-Fungicides) - Market size: $1.2B* (2016), Microbial based treatments, targeting insects (corn rootworm, stinkbug and lepidoptera) and fungi (fusarium and mildew)Bio X – Microbial based consumer trait products Products under development:

Business Model * Distribution channels A B Model A – Direct Market Access Model B – Market Access via partner Consolidated markets Partner Fragmented markets Co-development of corn bio-stimulants with Corteva

Product program Application Discovery Early Dev. Dev.stage 1 Dev. stage 2 Commercialization Product Bio Stimulants Corn Yield improvement under normal & drought Seed treatment Wheat Yield improvement under normal & drought Seed treatment Bio Pesticides Fusarium and seedlings disease(Corn) Protect from Fusarium, other soil diseases and mycotoxins Seed treatment Mildew, Fruit rot ( focus on Grapes) Protect from mildews and reduce chemical load Foliar Bio X Consumer trait A Add consumer trait P1, P2 Foliar ,seed treatment Lavie Bio (Ag-Biologicals) - Pipeline *

Ag Seeds - Mission & Products * Insect control traits- Lepidoptera, Coleoptera, HemipteraYield and environmental stress traits- Yield, drought, nitrogen usage efficiencyDisease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes Mission: Bring to market top-quality seeds with high-value traits, under the “Triple S” Concept – Safe, Secure and Sustainable food Products under development mainly via (i) GMO and (ii) Genome Editing : GMO - genetically modified organism: an organism whose genetic material has been altered by means of genetic engineeringGenome Editing - edits made to the existing genome

Insect Control * Diverse trait portfolio with novel Mode of Action ! Discover & develop novel proteins conferring resistance to key insects through new modes of action

* STK is a major Cotton & Soybean pestNo trait solution in the marketEV040030208 is a member of a gene family, 1st hit in a potential ‘gold mine’ of additional novel insecticidal genes Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments Insect Control - Example Oneway ANOVA; Tukey-Kramer HSD EV040030208 WT Gene Controlling Southern Green Stink Bug (STK)

Corn Yield Drought Nitrogen use efficiency Soybean Yield Drought Yield and Environmental Stress Product Candidates* Discovery Phase 1 (POC) Phase IV (Pre -Launch) 18m-24m 1-2 years Phase 2 (Early Development) Phase 3 (Adv. Dev & Regulation) 1-2 years 4-6 year 2-4 year Crop Trait Partner Product * *Timeline according to industry estimates**Collaborations with Bayer, were previously initiated with Monsanto

* Yield and Environmental Stress Collaboration ExampleBayer (Monsanto) Improvedseeds Gene discovery and trait optimization Development and commercialization Model plant validation Target plant validationand development CPB Collaboration period - 10 yearsObjective - improved seeds via biotechnologyCrops - corn, soybean, cotton, canolaTraits - (i) Yield/drought tolerance/fertilizer utilization (II) Fusarium resistance in corn Key terms - R&D and up-front payments - total ~$68MMilestone payments + royalties from sales$30M equity investment

Corn Fusarium stalk rot Soybean Asian Rust Banana Black Sigatoka Disease Resistance Pipeline: Discovery Phase 1 (POC) Phase IV (Pre -Launch) 18m-24m 1-2 years Phase 2 (Early Development) Phase 3 (Adv. Dev & Regulation) 1-2 years 4-6 year 2-4 year Crop Trait Partner Product * *Timeline according to industry estimates**Collaborations with Bayer, were previously initiated with Monsanto Disease Resistance GMO Product Candidates:* Discovery Phase 1 (Creation of Edits) 6m-12m Phase 2 (Field Testing) Phase 3 (Seed Production) 1-2 year Crop Partner 3-4 years 1-2 year Product Trait Banana Black Sigatoka Soybean Nematode Corn Fusarium stalk rot Genome Editing Disease Resistance Product Candidates:

Genome Editing Disease Resistance Example *

Biomica – Mission & Products * Mission: Discovery and development of novel therapiesfor microbiome-related human disorders using computational predictive biology Microbiome and small molecule based therapies for:Immuno-oncology (with ICI) – combination therapy for cancerMDRO (Multi Drug resistant organisms) – targeting antibiotic resistant bacteriaGI related disorders - GI inflammatory & functional disorders Products under development:

Big Biopharma is Investing More Through Partnerships * Obesity and metabolic disease 2014 Inflammatorybowel disease 2013 Ulcerative Colitis 2013 Crohn’s disease 2016 Inflammatorybowel disease 2016 Inflammatorybowel disease 2017 Gastrointestinal indications 2017 Crohn’s disease 2014 Inflammatorybowel disease 2016 Inflammatorybowel disease 2017 Immunoocncology 2016 Immunoocncology 2018 Inflammatorybowel disease 2018 Obesity and diabetes 2018 C. Ddiff, inflanim, bowel disease 2016 Diagnostics 2017

Pipeline * Program Indication / Target Discovery Preclinical Phase 1 Phase 2 Approach Immuno-oncology (with ICI) BMC121 Combination Therapyfor NSCLC BMC127 Combination Therapyfor NSCLC MDRO BMC201 C. difficile toxin-B GI related disorders BMC426 IBS BMC321 IBD BMC322 IBD Biological Small Molecule

Canonic – Mission & Products * Mission: To develop and bring to marketmedical grade cannabis through a revolutionary genomic approach Innovative products to address key market needs: Products under development: MetaYield* - Increased metabolite yieldUnican* - Verified variety stabilityPrecise* - Tailored metabolite profiles targeting:Chronic painPTSD – Post traumatic stress disorderCancer care * Finalized product names to be determined

Business Model * Seed production Varieties dev. Cannabis growth Formulation Distribution Canonic aims to develop elite cannabis varieties for commercialization of medical products directly or via partnerships Clinical validation & regulation Unique varieties Seeds Flowers Potential partnerships

Milestone Roadmap * Establishment of R&D growing facility Complete two cannabis growth cyclesEstablish agronomic protocols Build cannabis core collectionEstablish initial cannabis database 2019 First product trait demonstrated Complete three cannabis growth cyclesComplete establishment of proprietary cannabis database Expand core collection of cannabis varieties 2020 Finalize development of first improved variety Pre-commercial stageSeed increase to allow production Finalize formulation process 2021

Casterra – Mission & Products * Our mission: Providing stable supply for the growing market demand for castor oil Product:An integrated ag-solution for castor - proprietary castor seed varieties supported by novel agro-technical know-how and proprietary mechanical harvesting. Traditional cultivationLow yield (0.6 MT/Ha.)Manual harvest Current Practice: Common castor family size, tall shrub, hand-picked Casterra solution: Modern row-crop cultivation Compact plants, high densityHigh oil contentAdapted to commercial mechanical harvest

Business Model and Technological Position * Crusher Grower + Partner Revenue sharing with oil producers Oil/Cake Seed production Industrial oil users Breeding technology & genomics Seed production Grower Crusher Product Industrial oil users Breeding technology & genomics Seed sales - Integrated solution (inc. growth protocol & mechanical harvest) Partner Seed Grain Variety Oil/Cake Product Seed Grain Variety

Pipeline * Portfolio Pipeline Adaptable to mechanical harvest, Concentrated ripening, Uniformity, High grade oil % 1st generation: CR -712 Gold Pre-commercial & mechanical Harvesting Yield trials & Growth Protocol Early screening Research / Pre-Breeding Israel - E1-E2 Target market – D1-D2 Commercial Improved yield, High germination rate, Earliness 2nd generation: CR -103 Gold, CST-106 Gold Improved yield, compact architecture, plant type variable 2nd generation: CR-103, CR-106 Compact architecture, adapted to mechanical harvest, uniformity, high germination rate 1st generation: CR-712 Improved yield, Concentrated ripening, Uniformity, Droughty tolerance 3rd generation: CR-128 Gold CR-712 CR-103 CR- 106 CR-712G CR 103G CR 106G CR-128G Synergetic & affordable hybrids CR-1180 4th generation: CR Hybrids

* Annex II: Financial Fundamentals

Key Financials – Balance Sheet * Thousand US $ 30.06.2019 31.12.2018 Current Assets 47,795 55,488 Long-Term Assets 5,659 3,206 Total Assets 53,454 58,694 Current Liabilities 4,713 5,431 Long-Term Liabilities 5,883 2,957 Total Shareholders Equity 42,858 50,306 Total Liabilities & Shareholders Equity 53,454 58,694 Key Points: Cash position: ~46 million USD as of 30.06.2019 No debtEstimated net cash usage for 2019: $16-$18 millionListed on TASE (2007) and NASDAQ (2013)

Key Financials – P&L * Thousand US $ H1 2019 H1 2018 Q2 2019 Q2 2018 2018 Revenues 540 745 192 379 1,747 Gross Profit 368 196 91 114 295 Operating Loss (9,372) (9,619) (4,703) (4,673) (19,989) Loss (7,895) (10,155) (4,141) (4,769) (20,812)